Literature DB >> 24906981

Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002.

Michelle C Odden1, Abdul-Razak Amadu2, Ellen Smit2, Lowell Lo3, Carmen A Peralta3.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) and hyperuricemia often coexist, and both conditions are increasing in prevalence in the United States. However, their shared role in cardiovascular risk remains highly debated. STUDY
DESIGN: Cross-sectional and longitudinal. SETTING &amp; PARTICIPANTS: Participants in the National Health and Nutrition Examination Survey (NHANES) from 1988 to 2002 (n = 10,956); data were linked to mortality data from the National Death Index through December 31, 2006. PREDICTORS: Serum uric acid concentration, categorized as the sex-specific lowest (< 25th), middle (25th- < 75th), and highest (≥ 75th) percentiles; and kidney function assessed by estimated glomerular filtration rate (eGFR) based on the CKD-EPI (CKD Epidemiology Collaboration) creatinine-cystatin C equation and urinary albumin-creatinine ratio (ACR). OUTCOMES: Cardiovascular death and all-cause mortality.
RESULTS: Uric acid levels were correlated with eGFR(cr-cys) (r = -0.29; P < 0.001) and were correlated only slightly with ACR (r = 0.04; P < 0.001). There were 2,203 deaths up until December 31, 2006, of which 981 were due to cardiovascular causes. Overall, there was a U-shaped association between uric acid levels and cardiovascular mortality in both women and men, although the lowest risk of cardiovascular mortality occurred at a lower level of uric acid for women compared with men. There was an association between the highest quartile of uric acid level and cardiovascular mortality even after adjustment for potential confounders (HR, 1.48; 95% CI, 1.13-1.96), although this association was attenuated after adjustment for ACR and eGFR(cr-cys) (HR, 1.25; 95% CI, 0.89-1.75). The pattern of association between uric acid levels and all-cause mortality was similar. LIMITATIONS: GFR not measured; mediating events were not observed.
CONCLUSIONS: High uric acid level is associated with cardiovascular and all-cause mortality, although this relationship was no longer statistically significant after accounting for kidney function.
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Uric acid; albuminuria; cardiovascular mortality; chronic kidney disease (CKD); hyperuricemia; kidney function; risk factor

Mesh:

Substances:

Year:  2014        PMID: 24906981      PMCID: PMC4177300          DOI: 10.1053/j.ajkd.2014.04.024

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  27 in total

1.  Serum cystatin C concentration as a marker of renal dysfunction in the elderly.

Authors:  D Fliser; E Ritz
Journal:  Am J Kidney Dis       Date:  2001-01       Impact factor: 8.860

2.  Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II).

Authors:  H Finney; D J Newman; W Gruber; P Merle; C P Price
Journal:  Clin Chem       Date:  1997-06       Impact factor: 8.327

3.  Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study.

Authors:  B F Culleton; M G Larson; W B Kannel; D Levy
Journal:  Ann Intern Med       Date:  1999-07-06       Impact factor: 25.391

4.  A solid phase fluorescent immunoassay for the measurement of human urinary albumin.

Authors:  B M Chavers; J Simonson; A F Michael
Journal:  Kidney Int       Date:  1984-03       Impact factor: 10.612

Review 5.  Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?

Authors:  Richard J Johnson; Duk-Hee Kang; Daniel Feig; Salah Kivlighn; John Kanellis; Susumu Watanabe; Katherine R Tuttle; Bernardo Rodriguez-Iturbe; Jaime Herrera-Acosta; Marilda Mazzali
Journal:  Hypertension       Date:  2003-04-21       Impact factor: 10.190

6.  Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  J T Moriarity; A R Folsom; C Iribarren; F J Nieto; W D Rosamond
Journal:  Ann Epidemiol       Date:  2000-04       Impact factor: 3.797

7.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

8.  Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort.

Authors:  Kunitoshi Iseki; Yoshiharu Ikemiya; Taku Inoue; Chiho Iseki; Kozen Kinjo; Shuichi Takishita
Journal:  Am J Kidney Dis       Date:  2004-10       Impact factor: 8.860

9.  Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis.

Authors:  Vikas R Dharnidharka; Charles Kwon; Gary Stevens
Journal:  Am J Kidney Dis       Date:  2002-08       Impact factor: 8.860

10.  Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients.

Authors:  Shih-Ping Hsu; Mei-Fen Pai; Yu-Sen Peng; Chin-Kang Chiang; Tai-I Ho; Kuan-Yu Hung
Journal:  Nephrol Dial Transplant       Date:  2004-02       Impact factor: 5.992

View more
  46 in total

Review 1.  Management of secondary hyperparathyroidism: how and why?

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2017-01-02       Impact factor: 2.801

2.  Trends in the levels of urine and serum creatinine: data from NHANES 2001-2014.

Authors:  Ram B Jain
Journal:  Environ Sci Pollut Res Int       Date:  2017-03-06       Impact factor: 4.223

3.  The effect of electrolyte balance on the voice in hemodialysis patients.

Authors:  Saime Sagiroglu; Adem Doganer
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-08-21       Impact factor: 2.503

4.  Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial.

Authors:  Michael A Schwarzschild; Eric A Macklin; Rachit Bakshi; Shamik Battacharyya; Robert Logan; Alberto J Espay; Albert Y Hung; Grace Bwala; Christopher G Goetz; David S Russell; John L Goudreau; Sotirios A Parashos; Marie H Saint-Hilaire; Alice Rudolph; Joshua M Hare; Gary C Curhan; Alberto Ascherio
Journal:  Neurology       Date:  2019-09-04       Impact factor: 9.910

5.  Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia.

Authors:  Hiroshi Matsuo; Eiji Ishikawa; Hirofumi Machida; Yasuhide Mizutani; Akiko Tanoue; Takahiro Ohnishi; Tomohiro Murata; Shinya Okamoto; Toru Ogura; Yuki Nishimura; Hiroo Ito; Masashi Yasutomi; Kan Katayama; Shinsuke Nomura; Masaaki Ito
Journal:  Clin Exp Nephrol       Date:  2019-12-16       Impact factor: 2.801

6.  Serum Uric Acid Levels and Risk of Intracranial Atherosclerotic Stenosis: A Cross-Sectional Study.

Authors:  Lin Li; Jun-Xia Zhu; Xiao-He Hou; Ya-Hui Ma; Wei Xu; Chen-Chen Tan; Fu-Rong Sun; Hong-Qi Li; Qiang Dong; Lan Tan; Jin-Tai Yu
Journal:  Neurotox Res       Date:  2020-02-08       Impact factor: 3.911

Review 7.  Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.

Authors:  Richard J Johnson; George L Bakris; Claudio Borghi; Michel B Chonchol; David Feldman; Miguel A Lanaspa; Tony R Merriman; Orson W Moe; David B Mount; Laura Gabriella Sanchez Lozada; Eli Stahl; Daniel E Weiner; Glenn M Chertow
Journal:  Am J Kidney Dis       Date:  2018-02-27       Impact factor: 8.860

Review 8.  The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders.

Authors:  Roy G Cutler; Simonetta Camandola; Kelli F Malott; Maria A Edelhauser; Mark P Mattson
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

9.  Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia.

Authors:  Jeffrey D Lebensburger; Gary R Cutter; Thomas H Howard; Paul Muntner; Daniel I Feig
Journal:  Pediatr Nephrol       Date:  2017-04-05       Impact factor: 3.714

10.  SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.

Authors:  Muhammad Abdul-Ghani; Stefano Del Prato; Robert Chilton; Ralph A DeFronzo
Journal:  Diabetes Care       Date:  2016-05       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.